Increasing the Oral Bioavailability of 6-prenylnaringenin by Micellar Solubilization

PBMC Activity After Native vs. Micellar 6-PN Oral Intake Clinical Trial

Official title: Increasing the Oral Bioavailability of 6-prenylnaringenin by Micellar Solubilization

Status Completed

Clinical Trial Summary

Micellar encapsulation will be tested to increase the oral bioavailability in humans of 6-prenylnaringenin (6-PN) from hops (Humulus lupulus). The study follows a single dose (250 mg 6-PN), placebo controlled, randomized, double-blind, three armed crossover study design with ≥2-week washout periods. Plasma, urine and PBMC samples will be collected at intervals up to 24 h after intake of the native compound, the micellar formulation or placebo. The safety, pharmacokinetics and impact of oral prenylflavonoids on PBMC survival will be investigated.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• PBMC Activity After Native vs. Micellar 6-PN Oral Intake
• Pharmacokinetics of Native vs. Micellar 6-PN After Oral Intake
• Safety of Native vs. Micellar 6-PN After Oral Intake

• NCT number: NCT03286777
• Study type: Interventional
• Source: University of Hohenheim
• Status: Completed
• Phase: N/A
• Start date: June 22, 2017
• Completion date: July 1, 2018